<?xml version="1.0" encoding="UTF-8"?>
<p>Recently, there is no precise antiviral regime for the deterrence of HCV infection. Nevertheless, current standard treatment pegylated interferon-α (PEG IFN- α) in combination with ribavirin (RBV) have been employed with certain side effects and slow response rate especially in patients infected with HCV genotype 1a and1b [
 <xref ref-type="bibr" rid="B11">11</xref>,
 <xref ref-type="bibr" rid="B12">12</xref>]. Now a day, various novel antiviral inhibitors have been accounted showing a promising approach against HCV.
</p>
